This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this title
- Benchmark Chugai's performance against key rivals in the prescription pharmaceutical sector
- Evaluate the impact of Chugai's alliance with Roche, including forecast strong growth for the Genentech-derived mAb portfolio in Japan
- Assess the forecast performance of Actemra, the first monoclonal antibody product to be developed and successfully launched by a Japanese company
